Creating special antibodies to find disease-related protein changes
Official title: DIRECTED DISCOVERY AND VALIDATION OF ANTI-SPLICE-JUNCTION SITE Abs
Funded at Abbratech, INC. · NIH-11196584 · Data updated 2026-11-12
This project aims to create new tools, called antibodies, that can find specific changes in proteins linked to various diseases, including cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abbratech, INC. NIH-funded |
| Lab location | 1 site (Branford, UNITED STATES) |
| Project start | September 20, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $551,373 |
| NIH project number | 4R44GM156476-02 |
| Project ID | NIH-11196584 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with diseases where alternative splicing plays a role, particularly certain types of cancer, could eventually benefit from the insights and tools developed through this research.
✕Less likely to help
Patients whose conditions are not related to alternative splicing or specific protein isoform changes would likely not directly benefit from this particular research.
What this research studies
Many diseases, especially cancer, are linked to tiny changes in how our bodies make proteins, a process called alternative splicing. These changes can create unique protein forms that are hard to detect. This project is developing an innovative technology to create highly specific antibodies that can pinpoint these unique protein forms. By finding these specific protein changes, we hope to better understand diseases and develop new ways to treat them. The initial work will confirm existing antibodies and then use a new method to create even more precise ones, with a special focus on cancer-related proteins.
Why it matters
Potential benefit: If successful, this work could lead to better ways to identify disease-specific protein changes, potentially improving diagnosis and guiding the development of new treatments for conditions like cancer.
How similar studies have gone: This project introduces an innovative 'Epivolve' phage display technology, suggesting a novel approach to generating site-directed antibodies against splice variants.
Where this research is happening
-
Abbratech, INC.
Branford, United States Active
Researchers
- Principal investigator: Li, Xiaofeng — Abbratech, INC.
- Study coordinator: Li, Xiaofeng
Related research
Other NIH-funded projects on the same topics.
-
Antibody Platform for Protein Isoform Splice-Junctions
A fast-track NIH grant aims to create antibodies that specifically recognize unique splice-junctions in proteins, helping to better understand and treat diseases linked to alternative splicing.
-
Developing antibodies to fight COVID-19 using advanced technology
This study is working on developing special antibodies that can fight the COVID-19 virus, using a new method to make sure they can keep up with any changes the virus might make, which could help improve treatments for COVID-19 and other infections.
-
Developing antibodies to target specific cancer mutations
This study is working on new antibodies that can help the immune system better recognize and attack cancer cells with a specific KRAS mutation, aiming to make treatments more effective and safer for patients with these types of cancers.
-
Developing antibodies to target specific protein splice variants
This study is working on a new way to find and test special antibodies that can help us understand and treat diseases like cancer by focusing on how proteins are made in different forms, which can change how they behave in the body.
-
Validating antibodies for detecting modified proteins
This study is working to make sure that the tools scientists use to find certain proteins in the lab are more accurate and reliable, which will help improve research and treatments for patients.
-
A platform for quickly creating and testing antibodies
This study is working on a new way to quickly create and test special proteins called antibodies that can help treat diseases, so patients can get better treatments faster and more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.